Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results

Journal of Cardiovascular Medicine

Volumn 11, Issue 12, 2010, Pages 912-918

  Durin, Ornella ^a   Pedrinazzi, Claudio ^a   Inama, Giuseppe ^a  

^a Ospedale Maggiore di Crema   (Italy)

Author keywords

ACE inhibitors; angiotensin receptor blockers; atrial fibrillation; GISSI AF; renin angiotensin system

Indexed keywords

AMIODARONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; NITRATE; PERINDOPRIL; PLACEBO; RAMIPRIL; TRANDOLAPRIL; VALSARTAN;

CATHETER ABLATION; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HUMAN; LONG TERM CARE; META ANALYSIS; MODULATION; RADIOFREQUENCY ABLATION; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 78649320532     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32833cdd6f     Document Type: Review

References (37)

1. Go AS, Hyleck EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the Anticoagulation and Risk factors In Atrial fibrillation (ATRIA) study. JAMA 2001; 285:2370-2375.
2. Wijffels MC, Kirchhoff CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. Circulation 1995; 92:1954-1968.
3. Allessie MA, Konings K, Kirchhof CJ, Wijffels M. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol 1996; 77:10A-23A.
4. Caballero R, Delpon E, Valenzuela C, Longobardo M, Tamargo J. Losartan and its metabolite E31 74 modify cardiac delayed rectifier K+ currents. Circulation 2000; 101:1199-1205.
5. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin dependentand independentpathways. Cardiovasc Res 2003; 60:315-325.
6. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remdeling in atrial fibrillation. Circulation 2000; 101:2612-2617.
7. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of Angiotensin II type 1 receptor antagonist on electrical and structural remodelling in atrial fibrillation. JAm Coll Cardiol 2003; 41:2197-2204.
8. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, et al. Effects of angiotensin-converting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heartfailure. Circulation 2001; 104:2608-2614.
9. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54:456-461.
10. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with leftventriculardysfunction. Circulation 1999; 100:376-380.
11. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insights from the Studies Of Left Ventricular Dysfuntion (SOLVD)Trials. Circulation 2003; 107:2926-2931. (Pubitemid 36736634)
12. Alsheikh-Ali AA, Wang PJ, Rand W, Konstam MA, Homoud MK, Link MS, et al. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J 2004; 147:1061-1065.
13. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al.Atrialfibrillation and riskof clinical eventsin chronicheart failurewith and without leftventricularsystolic dysfunction: resultsfrom the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47:1997-2004.
14. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Blazer R, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: resultsfromthe Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149:548-557.
15. Wachtell K, Letho M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new onset atrial fibrillation and subsequent stroke compared to atenolol. The Losartan Intervention For End Point Reduction in Hypertension (LIFE) Study. JAm Coll Cardiol 2005; 45:712-719.
16. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in theoccurrence ofatrialfibrillation.JAm Coll Cardiol 2004; 44:159-164.
17. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, VALUE Trial Group. Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. Hypertension 2008; 26:403-411.
18. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106:331-336.
19. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et al. Useof enalapril to facilitate sinus rhythm maintenance after external cardioversion of long standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24:2090-2098.
20. Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006; 47:46-50.
21. Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27:1841-1846.
22. Hansson L, Lindholm NH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) Randomized Trial. Lancet 1999; 353:611-616. (Pubitemid 29087980)
23. Hansson L, Lindholm NH, Ekbom T, Dahlof B, Lanke J, Scherstén B, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish trial in old patients with hypertension-2 study. Lancet 1999; 354:1751-1756.
24. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI 3 data. Heart 2001; 86:527-532.
25. Salchian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J, et al. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007; 154:448-453.
26. Fazio G, Pizzuto C, Sutera L, Guttilla G, Di Gesaro G, Cascio C, et al. Inefficiency of rennin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart. Minerva Cardioangiol 2007; 55:311-315.
27. Richter B, Derntl M, Marx M, Lercher P, Gossinger HD. Therapy with angiotensin-converting enzyme inhibitors, antiotensin II receptors blockers and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007; 153:113-119.
28. Obadah Al, Chekakie M, Akar JG, Wang F, Al Mouradi H, Wu J, Santucci P, et al. The effects of statinsand rennin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007; 18:942-946.
29. Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, et al. Rationale and design of the GISSI-Atrial Fibrillation Trial: randomized, prospective, multicenter study on the use ofvalsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med 2006; 7:29-38.
30. The GISSI AF Investigators. Writing Commettee: Disertori M, Latini R, Maggioni AP, Barlera S, Di Pasquale G, Franzosi MG, et al. Valsartan for prevention of recurrent Atrial Fibrillation. N Engl J Med 2009; April 16:1606-1617.
31. Madrid AH, Peng J, Zamora J, Marin I, Bernal E, Escobar C, et al. The roleof angiotensin receptors blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis or randomized controlled clinical trials. PACE 2004; 27:1405-1410.
32. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Preventionofatrialfibrillationwith angiotensin-converting enzyme inhibitors and angiotensin receptors blockers. J Am Coll Cardiol 2005; 45:1832-1839.
33. Van den Berg MP, Crijns HJGM, van Veldhuisen DJ, Griep M, De Kam PJ, Lie KI. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail1995; 1:355-363.
34. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-Analysis: inhibition of renin-angiotensin system prevents newonset atrial fibrillation. Am Heart J 2006; 152:217-222.
35. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin systemon atrialfibrillation.JClin Pharmacol2006;46:21-28.
36. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by a way of abrogation of the renin-angiotensin system: a systematic reviewand meta-analysis. Am J Ther 2008; 15:36-43.
37. Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptors blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 2008; 4:67-73.